| Revenue growth | Highest Q1 revenue; Consolidated revenue grew 2.3% YoY. |
|---|---|
| Margins | EBITDA margin at 16.7%; PAT margin at 11.1%. |
| Demand visibility | Strong uptake in chronic therapies and U.S. respiratory market. |
Growth
One India revenue grew 12% YoY to INR 3,452 Cr. North America recorded $162 Mn revenue.
Outlook
Focus on chronic therapy expansion in India and ramping up gVentolin supply in the U.S. market.
Risks
EBITDA and PAT margins saw a YoY contraction from 25.6% to 16.7% and 18.7% to 11.1% respectively.
Last quarter's promises, checked
Delivered
- Guided 17 new launches in Trade Generics → Launched gVentolin, Yurpeak, and others (= BEAT)
- Guided India chronic mix at 60% → Delivered 60.4% (= BEAT)
- Guided US gVentolin launch in Q1 → Delivered Q1 launch (= BEAT)
Partly delivered
- Guided double-digit India growth → Delivered 12% (= PARTIAL)
Missed
- Guided FY27 EBITDA margin 18.5%-20% → Delivered 16.7% in Q1 (= MISS)
- Guided US revenue run-rate improvement → Delivered $162M vs $155M prev. quarter (= MISS)
Investor Presentation filed with BSE, NSE: CIPLA. Summary written with AI assistance from the document.
Cipla Ltd: key numbers
- Share price
- ₹1,340.20
- Market cap
- ₹1,08,271 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 32.1×Sector 47.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla Partnership
Cipla signed an exclusive licensing and supply agreement with SBP Group’s CTTQ for the drug Rolditamig Deuderuxtecan. This collaboration aims to accelerate therapy access in licensed markets.
Cipla Merger & Restructuring
Cipla Ltd. announced an internal restructuring where Aspergen Limited, India, acquired a 100% stake in Aspergen Inc., USA, from existing group subsidiaries.